|
Number of Patients
|
23
|
33
|
56
|
|
Sex-Female
|
6 (26.1%)
|
15 (45.5%)
|
21 (37.5%)
|
|
Age
|
49.9 ± 4.4
|
47.5 ± 6.7
|
48.52 ± 5.96
|
|
Race, African American (#)
|
1 (4.3%)
|
8 (24.2%)
|
9 (16.1%)
|
|
Cirrhosis
|
5(22.7%)
|
8(25.0%)
|
13 (24.1%)
|
|
Obesity
|
13(56.5%)
|
16(48.5%)
|
29(51.8%)
|
|
Diabetes mellitus
|
1(4.3%)
|
5(15.2%)
|
6(10.7%)
|
|
HCV genotype 1
|
16 (65.2%)
|
27 (81.8%)
|
43(76.8%)
|
|
Pretreatment ALT
|
96 ± 59
|
111 ± 79
|
104 ± 72
|
|
Pretreatment HCV RNA (IU/mL)
|
5,596,354 ± 6,524,048
|
4,424,606 ± 5,295,969
|
4,893,305 ± 5,788,661
|
|
High Viral Load (> 850,000 IU/mL)
|
17 (77.3%)
|
25 (75.8%)
|
42 (76.4%)
|
|
No Complete EVR (p < 4.27 e-05)
|
3 (13%)
|
22 (68.8%)
|
25 (45.5%)
|
|
No EVR (p < 0.005)
|
1 (4.3%)
|
12 (37.5%)
|
13 (26.3%)
|
|
Sustained Virologic Response (p < 0.0022)
|
15 (65.2%)
|
8 (24.2%)
|
23 (41.1%)
|
